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Background: We sought to determine if adult residents living at high altitude have developed sufficient adaptation
to a hypoxic environment to match the functional capacity of a similar population at sea level. To test this hypothesis,
we compared the 6-min walk test distance (6MWD) in 334 residents living at sea level vs. at high altitude.
Methods: We enrolled 168 healthy adults aged ≥35 years residing at sea level in Lima and 166 individuals residing at
3,825 m above sea level in Puno, Peru. Participants completed a 6-min walk test, answered a sociodemographics and
clinical questionnaire, underwent spirometry, and a blood test.
Results: Average age was 54.0 vs. 53.8 years, 48% vs. 43% were male, average height was 155 vs. 158 cm, average
blood oxygen saturation was 98% vs. 90%, and average resting heart rate was 67 vs. 72 beats/min in Lima vs. Puno. In
multivariable regression, participants in Puno walked 47.6 m less (95% CI −81.7 to −13.6 m; p < 0.01) than those in Lima.
Other variables besides age and height that were associated with 6MWD include change in heart rate (4.0 m per
beats/min increase above resting heart rate; p < 0.001) and percent body fat (−1.4 m per % increase; p = 0.02).
Conclusions: The 6-min walk test predicted a lowered functional capacity among Andean high altitude vs. sea level
natives at their altitude of residence, which could be explained by an incomplete adaptation or a protective
mechanism favoring neuro- and cardioprotection over psychomotor activity.
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Several studies have examined differences in exercise
capacity between acclimated, high altitude residents, and
non-acclimated controls [1-3]. Whether due to genetic
or developmental adaptations to hypoxic environments,
high altitude natives have higher exercise performance at
altitude when compared to lowlanders at high altitude [4].
Differences between highlanders and lowlanders have been
studied by measures such as maximal oxygen consumption
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2014efficiency, muscle response, arterial oxygen saturation, and
lactate buffering capacity [5].
Individuals non-acclimated to altitude have a decrease
in VO2 max upon assent to high altitude [5,6]. In contrast,
VO2 max is greater in highland dwellers of similar age, sex,
and body proportions [2,7-9], suggesting that theymay be bet-
ter adapted to live in hypoxic environments than lowlanders.
The present study uses the 6-min walk test (6MWT) to com-
pare functional capacity between high altitude residents and
lowlanders in their respective environments.
The 6MWT has a variety of uses in clinical settings to
test a patient's response to disease or medical interventions,
their functional capacity, and their predicted morbidity
and mortality [10-16]. This test was developed in 1963 to
evaluate people with respiratory or heart diseases, includ-
ing prognosis and functional capacity [17]. Due to theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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walking, the 6MWT provides information about how the
cardiovascular and pulmonary systems function together.
The exertion level achieved during the 6MWT is chosen
by the participant and is usually less than their maximal
exertion level [12]. However, activities of daily living are
similarly performed at exertion levels chosen by the indi-
vidual; therefore, the 6MWT is a good indicator of an in-
dividual's ability to perform activities of daily living [18].
Results from the 6MWT related to ascent to altitude
have been used as a measure of changes in functional
capacity among lowlanders at various altitudes, as well as
a method to predict who will be affected by acute altitude
sickness [19,20]. However, the 6MWT has not been used
as a method to compare functional capacities of high and
low altitude populations. By testing participants at their
residing altitudes, this study intends to determine whether
long-term high altitude residents have adapted to their en-
vironments to achieve the same functional capacity as sea
level residents. Thus, our primary objective was to investi-
gate the functional capacity of a sea level and high altitude
population by means of the 6MWT.
Methods
Study setting
The study population consisted of adults ≥35 years of
age living in the cities of Lima and Puno. Lima is the
highly urbanized capital of Peru located at sea level and
with a population of more than ten million. We con-
ducted our study in Pampas de San Juan de Miraflores, a
peri-urban shanty town located 25 km south of the city
center. Puno is an Andean City located at 3,825 m above
sea level and with a population of approximately 150,000.
The average temperature was 21.6°C in Lima and 16.1°C in
Puno. The study protocol was approved by the Institutional
Review Boards of the Johns Hopkins Bloomberg School of
Public Health in Baltimore, USA and A.B. PRISMA in
Lima, Peru. All participants provided verbal informed con-
sent after our research team read the entire informed con-
sent document to them and any questions were answered.
Study design
This is an ancillary study of a larger ongoing cohort
study conducted in Lima and Puno. In preparation for
study activities for this parent cohort study, we first
conducted a door-to-door household census of the
study areas from which an age-, sex- and site-stratified
population-based cohort of approximately 1,000 partici-
pants per site was derived [21]. At baseline, participants
responded to a face-to-face questionnaire regarding
sociodemographics and medical history. Field workers
measured weight, height, bioelectrical impedance, blood
pressure, and spirometry before and after bronchodilators,
and obtained a blood sample for analysis of cardiovascularand pulmonary biomarkers. We measured bioelectrical
impedance using the TBF-300A body composition analyzer
(TANITA Corporation, Itabashi-ku, Tokyo, Japan) to es-
timate lean mass, percent body fat, and water weight.
Participants were asked to provide venous blood sample
after 8 to 11 h of fasting. Blood was obtained by trained
phlebotomists in the sitting position and using universal
precautions. Plasma glucose was measured using an enzym-
atic colorimetric method (GOD-PAP; Modular P-E/Roche-
Cobas, Grenzach-Whylen, Germany), serum insulin using
electrochemiluminescence (Modular P-E/Roche-Cobas),
hs-C reactive protein using Latex (Tina-quant CRP-HS
Roche/Hitachi analyzer, Indianapolis, IN, USA), and
hemoglobin A1C using high-performance liquid chro-
matography (D10, BioRad, Munich, Germany). We mea-
sured lung function using the Easy-On-PC spirometer
(ndd, Zurich, Switzerland) following standard guidelines
[22]. All patients underwent bronchodilator-response
testing. We administered two puffs from a salbutamol in-
haler (100 mcg/puff) via a spacer and repeated spirometry
10 to 15 min later.
We then invited a random subset of 400 participants
(200 in Lima and 200 in Puno) from the parent cohort
study to participate in this ancillary study. We defined
healthy participants as those who did not have: a physical
disability that impaired walking; self-reported diagnosis of
heart failure, diabetes, asthma, COPD, active or a history
of pulmonary tuberculosis; prior pulmonary or thoracic
surgery, a self-reported history of daily smoking (i.e., ≥1
cigarette per day), a body mass index (BMI) ≥35 kg/m2,
systolic blood pressure (SBP) ≥140 mmHg, and diastolic
blood pressure (DBP) ≥90 mmHg, pre-bronchodilator
forced expiratory volume in 1 second (FEV1) or pre-
bronchodilator forced vital capacity (FVC) < 1 L (i.e., a
marker of impaired lung function in our study population),
post-bronchodilator FEV1/FVC < 70% or excessive erythro-
cytosis (i.e., hemoglobin ≥19 g/dL in women and ≥21 g/dL
in men) [23]. Of those who agreed to participate in this sub-
study, we conducted a preliminary evaluation of eligibility
criteria. The interview included a discussion of the study ob-
jectives, review of eligibility criteria, procedures, associated
risks, and benefits, and consent. Enrollees were then invited
to schedule an appointment to perform the 6MWT.
Six-minute walk test
The 6MWT was performed outdoors along a hard flat
course measuring 30 m, following standard guidelines
[24]. The 6MWT is a self-paced test and participants
can choose their own intensity of exercise. It measures
functional capacity as the majority of patients do not
achieve maximal sustained exercise capacity. Before the
test was performed, study staff measured height, weight,
and vital signs including pulse oximetry, heart rate, blood
pressure, and level of dyspnea and fatigue using the Borg
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read out loud instructions adapted from the American
Thoracic Society [24] to each participant to complete the
6MWT and gave standardized encouragement during the
6MWT to ensure comparability between participants and
sites. After the 6MWT was completed, vital signs and
Borg scale were repeated immediately.
Biostatistical methods
The primary outcome was distance walked during the
6MWT (i.e., 6MWD). The primary risk factor was alti-
tude of residence, defined as high altitude for partici-
pants in Puno and sea level for participants in Lima. We
used t tests to compare continuous variables between
groups if normally distributed and Mann–Whitney U
tests if non-normally distributed. We used chi-square or
Fisher exact tests whenever appropriate, if categorical
variables. We used multiple linear regression to model
6MWD as a function of altitude of residence and ad-
justed for age, sex, height, resting heart rate, SBP, change
in heart rate between the end of 6MWT and baseline,
percent body fat, height-adjusted FVC (FVC/height2), self-
report of walking ≥10 min at least 1 day per week as a
proxy for physical activity, number of people per household,
and having completed high school. We then developed
site-specific reference equations using multiple linear
regressions. The lower limit of normal for the 6MWD
was defined as the fifth percentile (i.e., μ^−1:64 σ^ ). We
conducted statistical analyses in R (www.r-project.org).
Results
Participant characteristics
Four hundred participants were invited to participate in
the study, but 66 (16%) met at least one of the exclusion
criteria: one participant was excluded due to age <35 years
old; one participant was excluded because of a FEV1 <1 L,
nine were excluded due to excessive erythrocytosis; six were
excluded because they had a BMI >35 kg/m2; 15 were ex-
cluded due to a post-bronchodilator FEV1/FVC <70%; and
37 were excluded based on a baseline SBP ≥140 mmHg or
DBP ≥90 mmHg on the day of the test. Of the remaining
334 participants, 168 resided in Lima and 166 in Puno. Age
and gender were similar in both groups. Participants in
Lima were shorter in height, had a higher body mass index,
higher pulse oximetry, and higher SBP but similar DBP, had
a significantly lower resting heart rate, and increased their
heart rate by more beats per minute during the 6MWT
than participants in Puno (Table 1). Both groups were simi-
lar in levels of fasting blood glucose, fasting blood choles-
terol, and triglycerides; participants in Lima had lower
hemoglobin concentration and higher insulin levels. Partici-
pants in Lima had lower levels of difficulty breathing and
fatigue, self-rated based on the Borg Scale. Participants in
Lima were less likely to have completed secondary schoolthan participants in Puno. One hundred of the 168 par-
ticipants in Lima migrated from a high altitude birth-
place, and 4 of 166 in Puno migrated to Puno from a
sea level birthplace. All participants have lived in their
respective cities where they performed the 6MWT for
at least the past 10 years.
Determinants of the 6MWD
In single variable analyses, the following variables were
important determinants of 6MWD in both the sea level
and high altitude groups: sex, age, height, change in heart
rate between end of 6MWT and baseline, hemoglobin,
lean mass, percent body fat, water weight, education level,
weekly exercise, FEV1/height
2, and FVC/height2 (Table 2).
In Figure 1, we show single variable relationships between
6WMD and selected risk factors. In multivariable linear
regression, however, variables that remained important
were living at high altitude, age, height, percent body fat,
and having completed high school (Table 3). Younger par-
ticipants walked a greater 6WMD than did older partici-
pants with a decrease of 1.4 m per year of older age.
Taller participants walked a greater 6MWD than shorter
participants with an increase of 1.1 m more per cm in-
crease in height. A greater increase in heart rate from
baseline also corresponded to a greater 6MWD, with an
increase 4.0 m more per beats/min increase above resting
heart rate.
Differences in 6MWD between participants at altitudes
of residence
In unadjusted analysis, living at high altitude was an
important determinant of 6MWD. Specifically, average
6MWD was 415 m (SD = 65) in Puno vs. 475 m (SD = 81)
in Lima (difference of 60 m, 95% CI 44 to 76; p < 0.001).
In multivariable linear regression, this difference remained
such that participants in Puno walked 47.6 m less than
did those in Lima (95% CI 13.6 to 81.7 m; p = 0.006).
There was no difference in 6MWD between those par-
ticipants in Lima who were born at high altitude vs.
born at sea level (p = 0.21) and the sample in Puno
consisted almost entirely of participants born at high
altitude. While we reported a difference in change in
heart rate between the end of the 6MWT and baseline
in Puno vs. Lima (mean 0.4 vs. 5.3 beats/min, respect-
ively; p < 0.001), we did not find a difference in change
in pulse oximetry (mean 0.54% vs. 0.41%; p = 0.27) or
SBP (7.6 mmHg vs. 7.1 mmHg; p = 0.70) between the
end of the 6MWT and baseline.
Reference equations for 6MWD in Lima and Puno, Peru
We defined site-specific reference equations for the
6MWD in Lima and Puno, adjusted for age, height,
weight, sex, and change in heart rate between the end of
test and baseline (Table 4). These models explained 54%
Table 1 Participant characteristics
Lima Puno P
Sample size 168 166
Demographics
Male,% 48% 43% 0.37
Age in years, mean (SD) 54 (11) 54 (10) 0.86
Clinical data, mean (SD)
Height, cm 154.8 (8.4) 157.5 (9.3) <0.01
Weight, kg 67.3 (9.9) 66.4 (10.9) 0.47
Body Mass Index, kg/m2 28.0 (3.3) 26.7 (3.4) <0.001
Systolic blood pressure, mmHg 116 (11) 107 (12) <0.001
Diastolic blood pressure, mmHg 69 (8) 69 (8) 0.78
Pulse oximetry,% 98.4 (1.2) 89.5 (3.0) <0.001
Resting heart rate, beats/min 66.9 (9.0) 71.6 (9.3) <0.001
Heart rate at the end of 6WMT, beats/min 72.2 (10.6) 72.0 (10.6) 0.85
Change in heart rate, beats/min 5.3 (6.8) 0.4 (6.2) <0.001
Pre-bronchodilator FEV1, L 2.8 (0.7) 2.9 (0.8) 0.19
Height-adjusted FEV1, L/m
2 1.1 (0.2) 1.1 (0.3) 0.79
Pre-bronchodilator FVC, L 3.6 (0.9) 3.7 (1.0) 0.12
Height-adjusted FVC, L/m2 1.5 (0.3) 1.5 (0.3) 0.51
Pre-bronchodilator FEV1/FVC% 77.5 (4.9) 76.7 (5.3) 0.14
Difficulty breathing after 6MWT (Borg Scale) 0.3 (0.6) 0.6 (0.9) <0.001
Fatigue after 6MWT (Borg Scale) 0.5 (0.9) 0.8 (1.0) <0.001
Laboratory data, mean (SD)
hsCRP, mg/dL 3.1 (4.0) 2.1 (3.4) 0.02
Insulin in uUnits/mL 10.4 (9.7) 7.5 (4.8) <0.001
Glucose, mg/dL 91.6 (10.3) 91.1 (19.9) 0.78
Cholesterol, mg/dL 199.8 (38.8) 199.5 (42.1) 0.95
High density lipoprotein cholesterol, mg/dL 41.0 (11.5) 42.3 (12.0) 0.33
Low-density lipoprotein cholesterol, mg/dL 126.3 (35.2) 125.2 (39.6) 0.78
Triglycerides, mg/dL 162.1 (102.0) 160.1 (107.6) 0.86
Hemoglobin, g/dL 13.5 (1.2) 16.9 (1.5) <0.001
Hemoglobin A1c, mmol/mol 5.6 (0.4) 5.8 (0.4) <0.001
Socioeconomic status data
Completed high school,% 64% 83% <0.001
Percent employed,% 68% 76% 0.13
People per household, mean (SD) 5.5 (2.3) 4.0 (1.9) <0.001
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and Puno, respectively.
Discussion
It is well documented that high altitude natives in several
settings around the world have made significant adaptations
to life in a hypoxic environment [1-9,26,27]. The majority
of these studies quantified these adaptations by testing
the exercise capacity of highlanders and lowlanders atincreasing altitudes and demonstrated highlanders had
an overall lower decrease in exercise capacity than low-
landers. Instead of this approach, our study quantified
the distance walked during a 6-min walk test by high-
landers and lowlanders in their respective environments
to determine to what extent high altitude adaptations have
allowed high altitude natives to approach the functional
capacity of a similar population at sea level. We found
that, after controlling for multiple variables, highlanders at
Table 2 Predictors of 6MWT
Lima Puno
Number 6MWD in m, mean (SD) P Number 6MWD in m, mean (SD) P
Age (years)
35–44 42 507 (79) <0.001 32 414 (57) 0.08
45–54 44 494 (58) 60 427 (70)
55–64 46 469 (86) 44 416 (64)
65–85 36 421 (72) 30 389 (58)
Gender (percent)
Males 80 506 (83) <0.001 71 446 (68) <0.001
Females 88 446 (67) 95 392 (51)
Height (cm)
130–144 19 431 (60) <0.001 10 371 (39) <0.001
145–159 92 450 (73) 86 397 (53)
160–200 57 529 (70) 70 444 (69)
Weight (kg)
40–59 41 440 (76) <0.001 45 396 (53) 0.06
60–79 107 478 (78) 100 423 (67)
80–101 20 529 (70) 21 417 (68)
Body mass index (kg/m2)
16–24 32 473 (89) 0.88 51 428 (77) 0.02
25–29 86 473 (80) 84 417 (57)
30–35 50 479 (77) 31 387 (54)
Systolic blood pressure (mmHg)
75–89 2 448 (106) 0.57 7 399 (36) 0.78
90–119 95 480 (74) 135 415 (64)
120–139 71 468 (89) 24 419 (74)
Diastolic blood pressure (mmHg)
40–64 43 458 (69) 0.24 52 408 (63) 0.64
65–79 107 482 (82) 97 417 (65)
80–99 18 468 (94) 17 422 (67)
Resting heart rate (beats per minute)
40–59 32 465 (67) 0.47 14 438 (67) 0.38
60–79 121 479 (82) 123 413 (64)
80–105 15 458 (95) 29 412 (65)
Active heart rate (beats per minute)
45–64 38 451 (69) 0.05 50 398 (51) 0.08
65–84 113 478 (78) 96 422 (69)
85–120 17 504 (108) 20 422 (65)
Delta heart rate (beats per minute)
< 0 24 447 (49) <0.001 72 394 (55) <0.001
0–14 131 470 (79) 92 431 (67)
15–35 13 569 (87) 2 430 (35)
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Table 2 Predictors of 6MWT (Continued)
Difficulty breathing after 6MWT (self-rating based on Borg Scale)
0 132 474 (80) 0.65 88 420 (66) 0.39
0.5–2 25 487 (91) 55 413 (63)
≥ 3 11 462 (64) 23 400 (62)
Fatigue after 6MWT (self-rating based on Borg Scale)
0 107 470 (80) 0.41 65 417 (65) 0.80
0.5–2 34 491 (85) 68 416 (63)
≥ 3 27 474 (76) 33 408 (68)
hsCRP (mg/dL)
< 1 50 478 (86) 0.03 76 412 (58) 0.65
1–2 63 492 (81) 63 414 (69)
3–35 55 452 (70) 27 425 (71)
Insulin (uUnits/mL)
0–4 36 479 (90) 0.92 63 427 (76) 0.06
5–10 71 475 (85) 64 400 (48)
10–100 61 472 (70) 39 419 (65)
Glucose (mg/dL)
60–79 17 472 (78) 0.57 30 405 (62) 0.67
80–99 121 478 (83) 110 418 (68)
100–300 30 461 (71) 26 414 (53)
High density lipoprotein cholesterol (mg/dL)
0–39 90 489 (89) 0.04 80 424 (67) 0.21
40–59 66 462 (68) 72 405 (58)
60–100 12 440 (57) 14 413 (80)
Triglycerides (mg/dL)
0–99 52 468 (79) 0.60 37 396 (55) 0.08
100–199 77 474 (78) 92 417 (67)
200–1,200 39 485 (89) 37 429 (64)
Hemoglobin (g/dL)
9–12 58 446 (70) <0.001 2 416 (39) <0.01
13–16 110 490 (85) 86 398 (58)
17–21 0 NA (NA) 78 434 (67)
Hemoglobin A1c (mmol/mol)
4–4.99 5 440 (58) 0.37 2 397 (49) 0.22
5–5.99 139 478 (84) 110 415 (67)
6–7 24 460 (64) 54 416 (60)
Low-density lipoprotein cholesterol (mg/dL)
0–74 12 516 (69) 0.21 12 446 (94) 0.22
75–149 118 472 (82) 119 413 (64)
150–325 38 471 (77) 35 411 (53)
Lean mass
30–44 88 442 (70) <0.001 92 391 (47) <0.001
45–54 52 496 (73) 43 441 (69)
55–75 28 536 (79) 31 448 (76)
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Table 2 Predictors of 6MWT (Continued)
Percent body fat (%)
10–24 40 513 (84) <0.01 46 455 (74) <0.001
25–34 79 469 (78) 67 404 (50)
35–50 49 453 (72) 53 393 (58)
Water weight (kg)
20–29 53 438 (69) <0.001 65 390 (47) <0.001
30–39 85 475 (74) 69 423 (66)
40–55 30 540 (78) 32 447 (75)
Education (level)
≤ Secondary 60 430 (74) <0.001 29 382 (42) <0.01
Higher, non-university 76 489 (72) 52 410 (62)
University 32 525 (70) 85 429 (68)
Income per month (soles)
< 550 27 429 (75) <0.001 49 399 (63) 0.07
550–1,499 116 483 (77) 69 428 (69)
≥ 1,500 18 516 (74) 19 410 (52)
Not available 7 29
Number of people per household
1–3 29 465 (99) 0.46 65 416 (71) 0.69
4–5 65 484 (77) 68 410 (59)
6–17 74 470 (76) 33 422 (66)
Number of days walking for 10 min or more per week
0 130 472 (82) 0.34 145 412 (65) 0.17
1 12 508 (82) 5 400 (51)
≥ 2 26 473 (72) 16 443 (62)
Number of days of exercise per week
0 156 470 (79) 0.02 149 410 (62) <0.01
1 8 550 (67) 5 469 (27)
≥ 2 4 499 (121) 12 456 (80)
Pre-bronchodilator forced expiratory volume in 1 s (liters)
1.0–1.49 4 338 (40) <0.001 3 346 (30) <0.01
1.5–1.99 21 414 (64) 18 380 (30)
≥ 2.0 143 487 (76) 145 421 (66)
Height-adjusted pre-bronchodilator forced expiratory volume in 1 s (L/m2)
0.0–0.99 46 429 (76) <0.001 49 393 (64) <0.01
1.0–1.49 113 490 (75) 101 420 (64)
≥ 1.5 9 519 (78) 16 451 (52)
Pre-bronchodilator forced vital capacity (liters)
1.0–1.99 2 371 (3) <0.001 3 346 (30) <0.001
2.0–2.99 54 429 (67) 40 383 (40)
≥ 3.0 112 499 (76) 123 427 (67)
Height-adjusted pre-bronchodilator forced vital capacity (L/m2)
0.0–1.49 94 445 (67) <0.001 91 395 (58) <0.001
1.5–1.99 65 510 (79) 63 434 (63)
≥ 2.0 9 529 (100) 12 464 (71)
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Table 2 Predictors of 6MWT (Continued)
Pre-bronchodilator FEV1/FVC (%)
60–69 11 482 (110) 0.92 20 418 (72) 0.95
70–84 148 474 (80) 138 414 (65)
≥ 85 9 481 (56) 8 417 (32)
Pulse oximetry (percent)
70–84 0 NA (NA) 0.40 8 401 (58) 0.66
85–94 1 406 (NA) 153 415 (65)
95–100 167 475 (81) 5 434 (72)
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than did lowlanders at sea level, i.e., a 48-m difference
in 6-min walk distance. This difference was greater
than the minimal clinically important difference for many
chronic respiratory conditions (Table 5) [10,28,29].
A shorter 6-min walk distance we observed indicating
a 13% lowered functional capacity is comparable to the
previously reported decrease in marathon time performed
by a trained high altitude native on a course ranging from
4,100 to 4,700 m in elevation. This time was 18.5% slower
than the world record at sea level but still faster than the
predicted time for a sea level native on a marathon course
at this altitude [30]. Despite the superior oxygen uptake
and pulmonary gas exchange, a 40% higher diffusing
capacity and greater lactic acid buffering in high altitude
natives [31,32], there is still a measurable impairment in
functional capacity at their altitude of residence. It is
unclear, however, whether the decrease in 6-min walk
distance is an incomplete adaptation or a protective adap-
tation among Andean high altitude dwellers. The psycho-
motor slowing observed in European, Native American,
and African altitude groups could be an adaptive rather
than a deficient trait, perhaps enabling accuracy of cognitive
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Figure 1 Single variable relationships between 6-min walk distance ashown that lower region-by-region brain glucose metabolic
rates in high altitude Quechuas compared to lowlanders,
which may be the result of a functional adaptation against
chronic hypoxia [34]. The lower change in heart rate before
and after the 6-min walk test in high altitude vs. sea level
dwellers may also help explain the observed shorter 6-min
walk distance. Heart rate is affected by both the sympa-
thetic and parasympathetic nervous systems; a balance
which is known to be different in hypoxic environments,
even after prolonged exposure [35,36]. Some suggest that
the lack of increase in heart rate may be a protective func-
tional adaptation which prevents an excess of adrenergic
stimulation during exercise [35-37].
The effects of high altitude on human health have
been studied using various approaches ranging from its
effects on athletic performance [5,6,26], to consequential
functional adaptations that arise among highlanders
including chronic mountain sickness and high-altitude
pulmonary hypertension [38,39]. Maximal cardiopulmo-
nary testing including peak VO2 has been shown to pre-
dict exercise capacity but has its limitations because the
very sick are unable to undergo this testing. In several
examples, a primary outcome of functional capacity has
been adequately demonstrated using the 6MWT in80 100 120 140
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nd selected risk factors.
Table 3 Multivariable linear regression of 6-min walk




City (Lima is reference) −47.6 (−81.7 to −13.6) <0.01
Age (years) −1.4 (−2.2 to −0.7) <0.001
Sex (male as reference) −13.5 (−39.8 to 12.8) 0.32
Height (cm) 1.1 (0.1 to 2.1) 0.04
Percent body fat (%) −1.4 (−2.6 to −0.3) 0.02
Systolic blood pressure (mmHg) 0.0 (−0.5 to 0.6) 0.87
Pulse oximetry (%) 1.0 (−1.7 to 3.8) 0.45
Log hsCRP (mg/dL) 5.0 (−1.7 to 11.3) 0.12
Hemoglobin (g/dL) 2.4 (−4.5 to 53.3) 0.44
Height-adjusted post-FVC (L/m2) 24.4 (−4.1 to 52.9) 0.09
Walks ≥10 min at least 1 day per week 14.6 (−1.4 to 30.6) 0.07
Resting heart rate (beats/min) 0.6 (0.0 to 1.3) 0.07
Change in heart rate between end
of 6WMT and baseline (beats/min)
4.0 (3.0 to 4.9) <0.001
Completed high school 24.9 (10.1 to 39.7) <0.01
Number of people per household −1.6 (−4.5 to 1.3) 0.28
Table 5 Minimal clinical important differences (MCID)
of 6-min walk distance (6MWD) for various chronic
respiratory diseases
Condition MCID for 6MWD (m)
Chronic obstructive pulmonary disease [28] 25 to 35
Idiopathic pulmonary fibrosis [10] 24 to 45
Pulmonary arterial hypertension [29] 33
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unable to complete other means of maximal cardiopul-
monary testing [10-13,15,16,18]. The 6-min walk test is
simpler than full cardiopulmonary testing, and in this
study, we demonstrate its simplicity in epidemiological
studies to compare functional capacity of two healthy
populations at different altitudes.
The results of this study suggest a lowered functional
capacity among high altitude residents of Puno, Peru,
vs. residents at sea level of Lima, Peru using a simple
and noninvasive test. The study design does not allow
us to conclude causation of the lowered functional
capacity among high altitude natives due to its cross-
sectional design. This study was also limited to a relativelyTable 4 Reference equations for 6-min walk distance in Lima
Lima (n = 168)
6MWD (m) R2 Subtract 1.64 × σ
for LLN
496:8−2:7 age−53:9ð Þ þ 1:6




468:8−2:4 age−53:9ð Þ þ 1:1
 height−156:0ð Þ þ 0:7
 weight−66:8ð Þ−37:5
I femaleð Þ þ 5:1
 Δ Heart rateð Þ
54.1% 90.9
Functions of age (in years), height (in cm), weight (in kg), sex, and change in hearthomogeneous population from two Peruvian cities,
which limits external validity. There are also limita-
tions in the study's high altitude population as it
includes only decedents of Andean background, which
differ in adaptations to hypoxia compared to Tibetan
populations [40].
Conclusions
In summary, after stratifying for variables shown to be
associated with the 6-min walk test, there was an im-
portant difference in the 6-min walk distance between
healthy adult residents at high altitude versus sea level.
This 48-m difference shown by multivariable regres-
sion is greater than the minimal important difference
observed in previous studies for various chronic re-
spiratory diseases, which varies between 24 and 45 m
[10,28,29]. Based on the results of this study, measured
differences in 6-min walk distance suggests that resi-
dents from the city of Puno, Peru, located at high alti-
tude (3,825 m above sea level) have not developed the
adaptations to their high altitude environment that are
necessary to bring them to an equivalent functional
capacity as similar residents of Lima, Peru, located at
sea level. Alternatively, the shorter 6-min walk distance
in healthy adults residing at high altitude versus sea
level could be explained by protective mechanisms in
which there is a lower psychomotor activity in favor of
increased neuro- and cardioprotection.and Puno, Peru
Puno (n = 166)
6MWD (m) R2 Subtract 1.64 × σ
for LLN





434:3−1:2 age−53:9ð Þ þ 2:0
 height−156:0ð Þ−1:3
 weight−66:8ð Þ−40:8
I femaleð Þ þ 2:68
 ΔHeart rateð Þ
30.5% 89.6
rate between the end of 6MWT and baseline (beats/min).
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